GlassScriptPhysician profile
Christopher Scott Nunes
NPI 1508821265
$14,077.76
in general payments reported to CMS, 2019-2025
48 companies · $1,964 in 2025
The $1,964 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,832 · 2020: $1,907 · 2021: $2,455 · 2022: $1,847 · 2023: $2,037 · 2024: $2,036 · 2025: $1,964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,947 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,946.53 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,279.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,216.08 | 2019-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $1,134.30 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $1,002.77 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $882.97 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $784.75 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $736.84 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $705.70 | 2021-2025 | |
| Amarin Pharma, INC. | $625.66 | 2019-2022 | |
| Astellas Pharma US INC | $495.41 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $462.58 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Takeda Pharmaceuticals U.S.A., INC. | $432.69 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $367.20 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $352.11 | 2019-2025 | Xifaxan, Trulance |
| Eisai INC. | $302.69 | 2020-2025 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Nunes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.